Press releases.

Press releases 2022

Press releases 2022

Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer

December 23rd 2022

Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha

December 8th 2022

Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

December 6th 2022

Immutep to Participate in The JMP Securities Hematology and Oncology Summit

December 2nd 2022

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

November 29th 2022

Immutep Receives Australian R&D Tax Incentive

November 14th 2022

Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

November 10th 2022

Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022

November 10th 2022

Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination

November 9th 2022

Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference

November 4th 2022

Immutep to Participate in Two Upcoming Investor Conferences

November 2nd 2022

Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

November 2nd 2022

Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

October 26th 2022

Immutep Quarterly Activities Report

October 25th 2022

Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

October 5th 2022

Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer

October 4th 2022

Immutep to Participate in Two Upcoming Investor Conferences

September 26th 2022

Immutep Receives A$2.7 million R&D Tax Incentive from French Government

September 23rd 2022

Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

September 14th 2022

Immutep Appoints LAG-3 Pioneer, Dr Frédéric Triebel to Board

September 13th 2022

Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

September 6th 2022

Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

August 30th 2022

Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd line PD-X Refractory NSCLC

August 1st 2022

Immutep Quarterly Activities Report

July 28th 2022

Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3

July 6th 2022

Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer

June 27th 2022

Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

June 4th 2022

Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022

June 2nd 2022

Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022

May 27th 2022

Immutep Presents New and Significant Data from the AIPAC Study

May 4th 2022

Immutep Quarterly Activities Report

April 29th 2022

Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting

April 28th 2022

Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients

March 30th 2022

Immutep Announces Publication of TACTI-002 Abstract at ESMO’s European Lung Cancer Congress 2022

March 24th 2022

Immutep to Present Biomarker and Multivariate Analysis from Phase IIb AIPAC Study in Metastatic Breast Cancer at ESMO’s Breast Cancer Congress 2022

March 18th 2022

Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525

March 18th 2022

Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer

March 10th 2022

Immutep Appoints Lucy Turnbull as Non-Executive Director

February 25th 2022

Immutep to Present at Healthcare Investor Conferences

February 24th 2022

Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022

February 18th 2022

Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor

February 11th 2022

Immutep to Present at February Investor Conferences

January 31st 2022

Immutep Quarterly Activities Report

January 25th 2022